Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cell lines have been established that secrete a matched set of human chimeric IgM, IgG1, IgG2, IgG3, IgG4, IgE, and IgA2 antibodies that are directed against the hapten 4-hydroxy-3-nitrophenacetyl. These chimeric antibodies secreted from mouse plasmacytoma cells behave exactly like their authentic human counterparts in SDS-PAGE analysis, binding to protein A and in a wide range of serological assays. The antibodies have been compared in their ability to bind human C1q as well as in their efficacy in mediating lysis of human erythrocytes in the presence of human complement. A major conclusion to emerge is that whereas IgG3 bound C1q better than did IgG1, the chimeric IgG1 was much more effective than all the other IgG subclasses in complement-dependent hemolysis. The IgG1 antibody was also the most effective in mediating antibody-dependent cell-mediated cytotoxicity using both human effector and human target cells. These results suggest that IgG1 might be the favoured IgG subclass for therapeutic applications.

Original publication




Journal article


J Exp Med

Publication Date





1351 - 1361


Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Cell Line, Complement Activating Enzymes, Complement C1, Complement C1q, Complement System Proteins, DNA, Recombinant, Electrophoresis, Polyacrylamide Gel, Genes, Immunoglobulin, Glycosylation, Haptens, Hemolysis, Humans, Immunoglobulins, Mice, Nitrophenols, Phenylacetates, Plasmacytoma, Plasmids, Transfection, Tumor Cells, Cultured